December 21, 2018 - Regulatory Dosing with candidate drug AP1189 in multiple-dose part of the Phase I study completed
December 10, 2018 - Regulatory SynAct’s candidate drug AP1189 exhibits continued favourable safety and plasma profiles in the multiple-dose part of the Phase I study
October 22, 2018 - Regulatory SynAct Pharma announced that AP1189 exhibits a favourable plasma profile in the Phase I study’s initial multiple-dose part
September 13, 2018 - Regulatory SynAct Pharma announced the start of the multiple-dose part of the Phase I study with AP1189
August 20, 2018 - Regulatory SynAct Pharma announced positive data from preclinical study in nephrotic syndrome with candidate drug AP1189
July 23, 2018 - Regulatory SynAct Pharma obtains regulatory approval for the implementation of the multiple-dose part in Phase I study with candidate drug AP1189
June 12, 2018 - Regulatory SynAct Pharma adapts the continued clinical development programme for AP1189 based on new results from the Phase I study
April 10, 2018 - Regulatory Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)
March 23, 2018 - Regulatory SynAct Pharma proposes a rights issue of SEK 22.4 million in order to increase the market potential for AP1189.
